tbuckley/cabot-search huggingface dataset:
Primary breast lymphomas: An Argentinian cooperative study
Authors: E. Gil Deza, M. Dragosky, I. Annetta, M. Marquez, A. Corzo, N. Gercovich, E. Morgenfeld, F. Tognelli, E. Rivarola, F. G. Gercovich
Journal: Journal of Clinical Oncology (2009)

e19555 Background: Primary Breast Lymphomas are rare tumors (less than 1% of all primary breast tumors). Because of that, the records of two institutions dedicated exclusively to the treatment of cancer (Hospital Municipal de Oncologia “Maria Curie” and Instituto Oncologico Henry Moore) have been working together in a single series. Objective: To make a retrospective study of the clinical onset, treatment and evolution of the patients with Primary Breast Lymphoma (PBL). Methods: Patients from hemato-oncological databases of both institutions, that presented PBL, were studied. A database containing characteristics of the population, clinical onset, treatments, evolution and survival Results: Gender F/M=2/15 pt. Mean age (range)=54.1 years (24–87). Pathology: Hodgkin's Lymphoma = 1 pt, NHL follicular = 8 pt, Large-Cell Diffuse NHL = 6 pt, lymphoplasmocytic NHL = 1 pt, Marginal Zone NHL = 1 pt. Stages: IA = 2 pt, IIA = 8 pt, IIIA = 1 pt, IVA = 6 pt. Radiotherapy: 11 pt. Polychemotherapy: CVP = 7 pt, COPP = 1 pt, CHOP = 2 pt, CNOP = 4 pt, CVP/CHOP = 1 pt, RCHOP = 1 pt, RESHAP = 1 pt. Response: CR16/16 evaluable pt. Evolution: Recurrence = 3 pt, Second tumors = 3 pt (breast cancer = 3 pt), Third tumors = 1 pt (melanoma = 1 pt). Survival. Dead = 4 pt. Alive with no illness = 12 pt, Alive under treatment = 1 pt. Conclusions: 1) Seventeen pt with PBL were identified. 2) Sixteen out of 17 were non-Hodgkin lymphomas. 3) Fifteen of 17 pt were women 4) Fourteen of the 17 cases affected only one breast. 5) Seven out of 17 cases were tumors of less than 5 cm. 6) Response reached 100% of the evaluable pt. 7) There was an important rate of second and third tumors (20%). 8) With a mean follow up time of 82 months, 75% of the population is alive and free of the illness. No significant financial relationships to disclose.
Giv As a Novel Prognostic Marker in Stage Ii Colon Cancer
Authors: P. Gibbs, P. Ghosh, P. Waring, B. Lafleur, A. Muranyi, S. Singh, P. Brunhoeber, J. Tie, B. Tran, J. Desai, R. Martinez, K. Janssen, A. Goel, S. Hu, V. Teichgräber, U. Rohr, R. Ridder, K. Shanmugam
Journal: Annals of Oncology (2014)
Humor therapy as a new concept in palliative care.
Authors: A. G. Kessler, U. Dreher, M. Mueller, G. Fischer, G. J. Wiedemann
Journal: Journal of Clinical Oncology (2010)

e19583 Background: Laughter is the best medicine. In our experience terminally ill patients still appreciate humor as much as healthy individuals. The purpose of humor therapy is the improvement of general contentedness and well-being of the patients by using several different humor interventions such as spontaenous joking, performing magic or the use of music instruments. Our project started in 2008 by training all staff on our palliative care unit (PCU) in humor techniques for use in everyday clinical practice and communication. The aim of our pilot study was to determine the feasibility of humor therapy as an additional offer for our terminal ill patients. Methods: In this prospective study all PCU team members were offered training by professional clowns in 12 teaching courses. Lessons consisted of interactive lectures, role plays, learning of humor techniques, use of “humor equipment” and development of patient questionnaire. Trained PCU members used humor techniques as part of routine care for the volunteering patients. Additionally twice a month a special humor day is held with professional clown performances for patients, their friends and family members. During the project the interior decoration of our PCU is also changed. Results: 24/29 members of our team participated in the teaching. More than 400 patients have attended the performances of the clowns with only few refusals. Most patients taking part in the humor interventions either by our staff or the clinic clowns experienced pleasure and contentment. When measuring pain by visual analog scale (VAS) the pain was less intense. Communication with depressed patients improved. Our study on quality of life (QoL) and refinement of humor techniques is ongoing. Updated data will be presented. Addtionally the project has had a positive influence on our team's job satisfaction and the working atmosphere. Regularly supervised courses for refreshing knowledge of theory and practice of humor are essential. Conclusions: Humor therapy is a new concept in palliative care. In our pilot study humor therapy was well accepted by patients and improved their QoL. Humor techniques are inexpensive, can easily be learned and had high acceptance rates by staff and patients. Further formal study on humor techniques and QoL is ongoing. No significant financial relationships to disclose.
Update on the Paris Classification of Superficial Neoplastic Lesions in the Digestive Tract
Journal: Endoscopy (2005)

Neoplastic lesions in the digestive-tract mucosa are termed "superficial" when the depth of invasion is limited to the mucosa and submucosa. The endoscopic appearance has a predictive value for invasion into the submucosa, which is critical for the risk of nodal metastases.The endoscopic morphology of superficial lesions can be assessed with a standard video endoscope after spraying of a dye--an iodine-potassium iodide solution for the stratified squamous epithelium, or an indigo carmine solution for the columnar epithelium. In 2002, a workshop was held in Paris to explore the relevance of the Japanese classification. The conclusions were revised in 2003 in Osaka in relation to the definition of the subtypes used in endoscopy and the evaluation of the depth of invasion into the submucosa. In Japan, the description of advanced cancer in the digestive-tract mucosa using types 1 - 4 is supplemented by a type 0 when the endoscopic appearance is that of a superficial lesion. Type 0 is divided into three categories: protruding (0 - I), nonprotruding and nonexcavated (0 - II), and excavated (0 - III). Type 0 - II lesions are then subdivided into slightly elevated (IIa), flat (IIb), or depressed (IIc). Nonprotruding depressed lesions are associated with a higher risk of submucosal invasion. After endoscopic resection, invasion into the submucosa is an important criterion for the necessity of additional surgical resection. Micrometer analysis of the depth of invasion in the specimen is more precise, and distinct cut-off limits have been established in the esophagus, stomach, and large bowel.The morphology of superficial and nonprotruding neoplastic lesions is relevant to the prognosis. Following endoscopic detection, the lesions are analyzed using chromoendoscopy and assigned a subtype of the type 0 classification. The choice between endoscopic or surgical treatment is based on this description.
Genomic Heterogeneity In Pediatric Acute Lymphoblastic Leukemia
Authors: Isaac Yaniv, Marta Jeison, Michal Hameiri-Grossman, Jacque Mardoukh, Nir Adam Sharon, Sarah Elitzur, Gil Gilad, Gali Avrahami, Batia Stark, Smadar Avigad
Journal: Blood (2013)
The pre-treatment PET scans SUV inversely correlates with overall survival (OS) of high grade NHL
Authors: A. Sukari, O. Wong, M. Balasubramaniam, D. Decker
Journal: Journal of Clinical Oncology (2006)

17543 Background: Parling-Lynch (Blood 2003; Abs, 102(11):4805). report a high discriminative power of maximum standard uptake value (SUV) in differentiating high and low grade lymphoma. This study examines the relationship between the pre-treatment (18)F-2-deoxy-2-fluoro-D-glucose Positron emission tomography (18-FDG PET) scans, SUV, overall survival (OS) and disease free survival (DFS) in high grade non-Hodgkin’s lymphoma (NHL). Methods: 33 patients with pathological diagnosis of aggressive NHL but without other malignancies were included; the patients had a pre treatment 18-FDG PET scan with calculated SUV. NHL was classified using WHO classification, IPI score was calculated using International Non-Hodgkin’s Lymphoma Prognostic Factors Project criteria. Cox Proportional Hazards Regression analysis was used to assess the effect of SUV and the grouped IPI Score on both overall survival and disease-free survival. Results: 29 patients have diffuse large B-cell lymphoma (DLBCL), 2 have Mantle cell lymphoma (MCL) and 2 have peripheral T-cell lymphoma (PTCL). Over a median follow up of 2.6 years (0.6–4.6), OS and DFS were 76% and 82%, respectively. Median SUV was 18.6 (1.6–55.9). Patients with higher SUV have higher risks of dying after adjusting for their IPI Score (p-value = 0.0038). Specifically, each additional unit of SUV is associated with a 9.8% increase in the hazard of death. Patients with higher IPI Score have higher risks of dying after adjusting for their SUV (p-value = 0.0017). Specifically, each additional level of IPI Score is associated with a 274.9% increase in the hazard of death. SUV is not a significant predictor of disease-free survival once IPI Score is already known/adjusted for (p-value = 0.0731). Patients with higher IPI Score have higher risks of relapse after adjusting for their SUV (p-value = 0.023). Conclusions: Pre-treatment PET scan SUV significantly affects overall survival in high grade NHL. Our data indicate statistically non significant correlation between SUV and DFS. These findings could be secondary to small study sample or short median follow up. No significant financial relationships to disclose.
Expression of the genes encoding the rat renal insulin-like growth factor-I system.
Authors: R Rabkin, M Brody, L H Lu, C Chan, A M Shaheen, N Gillett
Journal: Journal of the American Society of Nephrology (1995)

Insulin-like growth factor-I (IGF-I) modulates renal function, growth, and repair. IGF-I produced in the kidney is one component of the intrarenal IGF-I system comprising the IGF-I receptor (IGF-IR) and six IGF-binding proteins (IGFBP). Because of the physiologic importance of IGF-I and its potential therapeutic properties, the renal sites of mRNA synthesis for IGF-I, IGF-IR, and IGFBP-I through IGFBP-5 were characterized in rat kidney by in situ hybridization. Anatomical heterogeneity was prominent. IGF-I mRNA was present in the thick ascending limb of Henle in the outer medulla, whereas IGF-IR mRNA was diffusely present at low levels throughout the kidney. IGFBP-I mRNA was localized to cells within the distal convoluted tubules as well as the thick ascending limb of Henle. IGFBP-2 mRNA was expressed in glomeruli, medullary ray collecting ducts, pelvic smooth muscle and uroepithelium, and the papilla tip; IGFBP-3 mRNA was localized to the cortical interstitium, whereas IGFBP-4 mRNA was expressed in proximal tubules, medullary ray collecting ducts, and glomeruli. IGFBP-5 was strongly positive throughout the medulla with lesser expression in the distal convoluted tubules and glomeruli. This study highlights the complexity of the intrarenal IGF-I system. The striking heterogeneity of IGFBP gene expression suggests that the various IGFBP may have diverse modulatory effects on the action of IGF-I or discrete effects of their own.
Cholecalciferol supplementation in patients taking anti tuberculosis treatment
Authors: Surendra Kumar Chityala
Journal: European Respiratory Journal (2014)

Aim: To Assess dosage and duration of VitD supplementation in Pts taking ATT

Methods: 300 pts started on ATT under RNTCP were enrolled in the study.Initial 25OHD3 were measured and eligible pts were divided into 2 groups, one receiving 60K IU per week for 2 months and other receiving 2500IU per day for 6 months. 25OHD3 levels were measured at 2 and 6 months.

Results: Of the 300 pts, 247 were found to have deficient /insuffient levels of VitD3.Of these 153 were females and 94 were males. They were divided into 2 groups. One group was given 60K IU per week for 2 months and other group was given 2500IU per day for the total duration of 6 months.

At the end of 2 months, both groups reached optimum levels of 25OHD3. Again, they were tested at 6 months, The group that was given VitD for 2 months had 34 patients with falling levels. While the group on daily VitD had optimum levels.

Conclusions: All pts general condition improved when pts were started on VitD supplementation. Sputum conversion rates were similar in both groups. Some patients on 60K group were deficient again by 6 months indicating need for continued supplementation. Pts on 2500 group had defaulted some doses but levels were maintained at 6 months.

The dose and duration for correct supplementation has to be reached with bigger samples.
Hypertension in Patients with Neurovascular Compression Is Associated with Increased Central Sympathetic Outflow
Authors: Hans P. Schobel, Helga Frank, Ramin Naraghi, Helmut Geiger, Elmar Titz, Karsten Heusser
Journal: Journal of the American Society of Nephrology (2002)

ABSTRACT. Recent data suggest a causal relationship between essential hypertension and neurovascular compression (NVC) at the rostral ventrolateral medulla. An increase of central sympathetic outflow might be an underlying pathomechanism. The sympathetic nerve activity to muscle was recorded in 21 patients with hypertension with NVC (NVC+ group) and in 12 patients with hypertension without NVC (NVC− group). Heart rate variability, respiratory activity, BP, and central venous pressure at rest and during unloading of cardiopulmonary baroreceptors with lower-body negative pressure and during a cold pressor test were also measured. Resting sympathetic nerve activity to muscle was twice as high in the NVC+ group compared with the NVC− group (34 ± 22 versus 18 ± 6 bursts/min; P < 0.05). Resting heart rate (P = 0.06) and low- to high-frequency power ratio values (P = NS) (as indicators of cardiac sympathovagal balance) tended to be augmented as well in the NVC+ group. The sympathetic nerve activity to muscle response to the cold pressor test was increased in the NVC+ group versus the NVC− group (+15 ± 11 versus 6 ± 12 bursts/min; P = 0.05), but hemodynamic and sympathetic nerve responses to lower-body negative pressure did not differ between the two groups. It is concluded that NVC of the rostral ventrolateral medulla in patients with essential hypertension is accompanied by increased central sympathetic outflow. Therefore, these data support the hypothesis described in the literature: in a subgroup of patients, essential hypertension might be causally related to NVC of the rostral ventrolateral medulla, at least in part, via an increase in central sympathetic outflow.
Thrombolysis for Acute Myocardial Infarction in a District General Hospital
Authors: H Dalton, D Chappel, R Climie
Journal: Journal of the Royal Society of Medicine (1989)

We report our experience in establishing thrombolysis as a routine part of the management of patients with acute myocardial infarction in our hospital; with particular reference to the effectiveness of the policy, safety and delays in administration.
High-dose chemotherapy for metastatic breast cancer.
Authors: A Recht
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.684 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636793 High-dose chemotherapy for metastatic breast cancer. A RechtxA RechtSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.684 PDF "High-dose chemotherapy for metastatic breast cancer.." Journal of Clinical Oncology, 14(2), pp. 684–685© 1996 by American Society of Clinical Oncology
Carcinogenicity of Halo-Ethers. II. Structure-Activity Relationships of Analogs of Bis(chloromethyl)ether&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN4"&gt;4&lt;/xref&gt;
Authors: B. L. van Duuren, C. Katz, B. M. Goldschmidt, K. Frenkel, A. Sivak
Journal: JNCI Journal of the National Cancer Institute (1972)

Six chloro compounds related to the carcinogen bis(chloro-methyl)ether were tested for carcinogenic activity by subcutaneous injection in ICR/Ha mice and/or as initiating agents in 2-stage carcinogenesis on mouse skin. Two compounds, bis(α-chloroethyl)ether and 2,3-dichloro-tetrahydrofuran, showed tumor-initiating activity. A third compound, chloromethyl methyl ether, included in the subcutaneous injection experiments, had been shown earlier to be an effective initiating agent. All 6 compounds induced subcutaneous sarcomas in mice, but only 2 of the 6, chloromethyl methyl ether and bis(α-chloroethyl)ether, caused significant numbers of sarcomas at the injection site. None of the compounds induced significant incidences of tumors at sites distant from the injection site. Studies on the rate of hydrolysis of these 6 compounds and other related compounds tested earlier showed a good correlation between chemical reactivity and carcinogenicity. Chloromethyl methyl ether and bis(chloromethyl)ether did not affect the Tm and buoyant density of salmon sperm DNA. The unlabeled compounds also did not yield simple isolable products on reaction with purines or DNA under conditions where other direct-acting alkylating carcinogens did.
Delayed-Hypersensitivity Reactions to Soluble Membrane Antigens of Human Malignant Lung Cells2
Authors: Ariel C. Hollinshead, T. H. M. Stewart, R. B. Herberman
Journal: JNCI Journal of the National Cancer Institute (1974)

Membrane preparations of human lung cancer cells, of “normal” lung cells from the same patient, and of normal lung cells from a healthy accident victim did not produce delayed-hypersensitivity reactions when 0.1 ml amounts, containing a range of 17–1232 μg membrane protein, were used in 48 intradermal skin tests of lung cancer patients. When these same membrane preparations were subjected to sequential, low-frequency sonication and the soluble portions of the membranes were partially separated on Sephadex G-200 into high- and lowmolecular weight protein fractions, 50 of 106 tests with fractions of lung cancer sonicates and 19 of 106 of “normal” lung-sonicate fractions from the cancer patients produced positive delayed-hypersensitivity skin reactions in autologous and allogeneic lung cancer patients. A patient with epidermoid lung cancer was also tested with fractions from normal lung cell-membrane sonicates obtained from the healthy accident victim; the high-molecular weight fraction produced a borderline positive response. Allogeneic tests on a patient with epidermoid lung cancer were performed with the soluble antigens, both from epidermoid cancer cells and from metastatic tumors growing in the lungs of patients with intestinal and cervical cancers; only the epidermoid lung cancer-soluble antigens gave positive tests. The soluble antigens were further separated by special gradient gel electrophoresis and elution of sliced regions of the gels. A total of 99 skin tests on 9 patients with oat cell carcinoma, epidermoid carcinoma, and adenocarcinoma were performed with the soluble antigens obtained from these gel regions prepared from 5 tumors, 5 adjacent lung preparations, and healthy lung. Positive skin reactions to antigens from adjacent lung and healthy lung preparations were mainly from regions I and II. Positive skin reactions to antigens from epidermoid carcinomas were mainly from regions I, II, and III. The strongest positive delayed-hypersensitivity skin reactions were to oat cell carcinoma and adenocarcinoma antigens from regions III and IV. Reactions were negative in a nonanergic patient with lymphosarcoma arising in the bronchus and in a nonanergic patient with breast cancer when tested with antigens from all gel regions of a healthy lung preparation. A total of 9 patients with malignant, nonpulmonary disease were skin-tested with all gel regions from a preparation of epidermoid lung cancer; all skin tests were negative. Thus skin tests in which separated lung cancer-soluble antigens are used produce delayed-hypersensitivity responses in lung cancer patients. We concluded that this reactivity was directed to certain antigens also present in some normal lung preparations as well as to certain antigens in lung cancer preparations which appeared to differ from the normal antigens, thus suggesting some tumor specificit.
Upregulation of Integrin 6/β1 and Chemokine Receptor CCR1 by Interleukin-12 Promotes the Migration of Human Type 1 Helper T Cells
Authors: Lucia Colantonio, Andrea Iellem, Barbara Clissi, Ruggero Pardi, Lars Rogge, Francesco Sinigaglia, Daniele D’Ambrosio
Journal: Blood (1999)
Extending the platinum-free interval (PFI) with a non-platinum therapy in platinum (P)- sensitive recurrent ovarian cancer (OC): Results from the SOCRATES retrospective study
Authors: S. Pignata, F. Odicino, G. Scambia, G. Cormio, D. Katsaros, G. Stellato, P. Scollo, B. Costa, G. Magni, R. V. Iaffaioli
Journal: Journal of Clinical Oncology (2006)

5093 Background: Chance of response to P is correlated to PFI (Markman, J Clin Oncol 1991). It has been proposed that extending PFI by interposing non-P therapy increase activity of delayed P retreatment in patients (pts) with P-sensitive recurrent OC, but this strategy is based on data from small series. The SOCRATES study retrospectively assessed the pattern of treatment of a cohort of pts with P-sensitive recurrent OC. Methods: Data of pts treated between 2000 and 2002 at 37 centers were collected in 2005. Pts with recurrent OC were eligible if P-sensitive [interval from end of first line to relapse (RFI) &gt; 6 months]. Results: Data on chemotherapy at relapse were available in 428 pts. RFI was 6–12 months in 40% and &gt;12 months in 60%. Pts received a 2 nd (100%), 3 rd (80%), 4 th (50%), 5 th (28%), 6 th (12%) line of chemotherapy. 282 pts (65.9%) received P at first relapse (Group A) after a median RFI of 19 months, with a 74.4% response rate (RR) out of 246 evaluable pts. 67 pts (15.7%) received non-P at first relapse after a median RFI of 9.6 months, with a RR of 44.6% out of 56 evaluable pts, and then received P at later relapse after a median PFI of 23 months, with a 57.4% RR out of 47 evaluable pts (Group B). 79 pts (18.5%), with a median RFI of 8.4 months, had a on-P 2 nd line with a RR of 28.8% out of 66 evaluable pts, and never received P later (Group C). The difference in RR to P given as 2 nd line and delayed P is statistically significant (p = 0.02, Fisher exact test). Median overall survival was 27.2, 26.1 and 16.8 months for Group A, B and C, respectively. Conclusions: With the limits of a retrospective study, our data show that, although P was given in the group B after a similar PFI than in the group A, due to the interposition of a non-P therapy, activity of P was higher when given immediately after relapse than when postponed at subsequent lines. Overall, these data suggest that P-sensitive pts should receive P as soon as possible, and delaying it may preclude the chance of receiving the best treatment. (Study sponsored by GlaxoSmithKline). No significant financial relationships to disclose.